The pharmacological management of migraine, part 2: Preventative therapy

P and T

Volumn 33, Issue 8, 2008, Pages 480-487

  DeMaagd, George ^a  

^a UNION UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIMIGRAINE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CENTRAL MUSCLE RELAXANT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESIPRAMINE; FLUOXETINE; METOPROLOL SUCCINATE; MIRTAZAPINE; NADOLOL; NEFAZODONE; NORTRIPTYLINE; PROPRANOLOL DERIVATIVE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN SUCCINATE; TIMOLOL; TIMOLOL MALEATE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

BLOOD DYSCRASIA; BLOOD PRESSURE FLUCTUATION; CLINICAL FEATURE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; IMPOTENCE; LIVER DISEASE; MIGRAINE; MYOPIA; NEPHROLITHIASIS; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PATIENT MONITORING; PROPHYLAXIS; QT PROLONGATION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VIVID DREAM; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 51549119510     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Silberstein SD, for the U.S. Headache Consortium. Practice Parameter: Evidence-Based Guidelines for Migraine Headache (An Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-762.
2. Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: www.aan.com/public/practiceguidelines/03.pdf/. Accessed August 2007.
3. Diamond S, Bigal ME, Silberstein S. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-363.
4. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. U.S. Headache Consortium. Available at: www/aan.com/professional/ practice. Accessed August 2007.
5. McCory DC, Matchar DB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache: Overview of program description and methodology. Available at: www.aan.com/public/practiceguidelines/03.pdf. Accessed August 2007.
6. Bekes M, Matos L, Rausch J, et al. Treatment of migraine with propranolol (Letter). Lancet 1968;2:980.
7. Wideroe TE, Vigander T. Propranolol in the treatment of migraine. Br Med J 1974;2:699-701.
8. Forssman B, Henriksson KG, Johansson V, et al. Propranolol for migraine prophylaxis. Headache 1976;16:238-245.
9. Borgesen SE, Nielsen JL, Moller CE. Prophylactic treatment of migraine with propranolol. Acta Neurol Scand 1974;50:651-656.
10. Diamond S, Medina JL. Double-blind study of propranolol for migraine prophylaxis. Headache 1976;16:24-27.
11. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Elmsford, NY: Pergamon Press; 1990:187-243.
12. Andersson KE, Vinge E. Beta-adrenoreceptor blockers and calcium antagonists in the prophylaxis of migraine. Drugs 1990;39:355-373.
13. Limmroth V, Mummel P. Migraine prophylaxis: Beta-blockers. In: Diener HD, ed. Drug Treatments of Migraine and Other Headaches. Monographs Clin Neurosci 2000;17:256-268.
14. Nadelmann JW, Phil M, Stevens J, et al. Propranolol in the prophylaxis of migraine. Headache 1985;26:175-186.
15. Zigelman M, Kuritzky A, Appel S, et al. Propranolol in the prophylaxis of migraine: Evaluation of spectral analysis of beat-to-beat heart rate fluctuations. Headache 1992;32(4):169-174.
16. Diamond S, Kudrow L, Stevens J, et al. Long-term study of propranolol in the treatment of migraine. Headache 1982;22:268-271.
17. Pascual J, Polo JM, Berciano J. The dose of propranolol for migraine prophylaxis: Efficacy of low doses. Cephalalgia 1989;9(4):287-291.
18. Carroll JD, Reidy M, Savundra PA, et al. Long-acting propranolol in the prophylaxis of migraine: A comparative study of two doses. Cephalalgia 1990;10:101-105.
19. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004;(2):CD003225.
20. Sudilovsky A, Elkind AH, Ryan RE Sr., et al. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache 1987;27:421-426.
21. Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. Headache 1986;26:490-493.
22. Gallagher MR, Stagliano RA, Sporazza C. Timolol maleate, a beta blocker, in the treatment of common migraine headache. Headache 1987;27:84-86.
23. Steiner TJ, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: Parallel-group comparison with placebo and dose-ranging follow-up. Headache 1987;28:15-23.
24. Johannsson V, Nilsson LR, Widelius T, et al. Atenolol in migraine prophylaxis: A double-blind cross-over multicentre study. Headache 1987;27:372-374.
25. Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache 1983;23:188-190.
26. Worz R, Reinhardt-Benmalek B, Grotemeyer K-H, et al. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura: Randomized double-blind cross-over multicenter study. Cephalalgia 1991;11(Suppl 11):152-153.
27. van de Ven LLM, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: A placebo-controlled study. Cephalalgia 1997;17:596-599.
28. Diener HC, Hartung E, Chrubasik J. Acetylsalicylic acid in migraine prophylaxis: A double-blind study in comparison with metoprolol. Cephalalgia 1997;17:434.
29. Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985;25:320-324.
30. Kozubski W, Prusinski A. Sodium valproate versus propranolol in the prophylactic treatment of migraine. Neurol Neurodur Pol 1995;29:937-947.
31. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997;54:1141-1145.
32. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251(8):943-950.
33. Ashrafi MR, Shabanian R, Zamani GR, et al. Sodium valproate versus propranolol in paediatric migraine prophylaxis. Eur J Paediatr Neurol 2005;9(5):333-338.
34. Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med 2001;38:621-627.
35. Limmroth V, Michel MC. The prevention of migraine: A critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001;52(3):237-243.
36. Ferrari A, Sternieri E, Ferraris E, Bertolini A. Emerging problems in the pharmacology of migraine: Interactions between triptans and drugs for prophylaxis. Pharmacol Res 2003;48(1):1-9.
37. 1b/1d agonist: Differential effects of propranolol, nadolol, and metoprolol. J Clin Pharmacol 2001;52:69-76.
38. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-699.
39. Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches: The role of antidepressants. Neurol Sci 2004;25(Suppl 3):S171-S175.
40. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003;7(1):51-54.
41. Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci 2006;27(8):410-415.
42. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973;36:684-690.
43. Ziegler DK, Hurwitz A, et al. Migraine prophylaxis: A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486-489.
44. King DS, Herndon KC. Headache disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, et al., eds. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. Norwalk, CT: Appleton & Lange; 2005:1105-1121.
45. Alldredge BK. Neurologic disorders: headache. In: Koda-Kimble MA, Young YL, eds. Applied Therapeutics: The Clinical Use of Drugs, 8th ed. Baltimore: Lippincott Williams & Wilkins; 2005:52-1-52-27.
46. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992;32(2):101-104.
47. Diamond S, Freitag FG. The use of fluoxetine in the treatment of headache. Clin J Pain 1989;5:200-201.
48. Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005;(3):CD002919.
49. Gardner DM, Lynd LD. Sumatriptan contraindications and serotonin syndrome. Ann Pharmacother 1998;32:33-38.
50. Shapiro RE, Tepper SJ, et al. The serotonin syndrome, triptans and the potential for drug-drug interactions. Headache 2007;47:266-269.
51. Wooltorton E. Triptan migraine treatment and antidepressants: Risk of serotonin syndrome. Can Med Assoc J 2006;175(8):874.
52. Eadie M. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001;15(2):105-118.
53. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999;39:192-199.
54. Ozyalcin SN, Talu GK, Kiziltan E et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45:144-152.
55. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: Randomized double-blind, crossover study. Clin Neurol Neurosurg 2004;107(1):44-48.
56. Levy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol 2003;18(5):301-303.
57. Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969;21:263-268.
58. Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: An open-label study. Headache 2001;41:465-474.
59. D'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms, and cluster headache: A review of their efficacy and tolerability. Neurol Sci 2007;28(Suppl 2):S188-S197.
60. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;(3):CD003226.
61. Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: From clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007;28(4):188-195.
62. Sorensen KV. Valproate: A new drug in migraine prophylaxis. Acta Neurol Scand 1988;78:346-348.
63. Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002;102(2):92-94.
64. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-1659.
65. Freitag FG. Divalproex in the treatment of migraine. Psychopharmacol Bull 2003;37(Suppl 2):98-115.
66. Kinze S, Clauss M, Reuter U, et al. Valproic acid is effective in migraine prophylaxis at low serum levels: A prospective open-label study. Headache 2001;41:774-778.
67. Lenaerts M, Bastings E, Sianard J. et al. Sodium valproate in severe migraine and tension-type headache: An open-label study of long-term efficacy and correlation with blood levels. Acta Neurol Belg 1996;96:126-129.
68. McNamara JO. Drugs effective in the therapy of epilepsies. In: Oilman AG, Hardmen JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. Elmsford, NY: Pergamon Press, 2001:521-547.
69. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: A double-blind placebo-controlled study. Headache 2001;41:968-975.
70. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004;291(8):965-973.
71. Peres MF, Mercante JP, Tanuri FC, et al. Chronic migraine prevention with topiramate. Headache 2006;7(4):185-187.
72. Li HL, Kwan P, Leung H, et al. Topiramate for migraine prophylaxis among Chinese populations. Headache 2007;47(4):616-619.
73. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814-823.
74. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache 2007;47(2):170-180.
75. Rapoport A, Mauskop A, Diener HC, et al. Long-term migraine prevention with topiramate: Open-label extension of pivotal trials. Headache 2006;46(7):1151-1160.
76. Silberstein SD, Feliu AL, Rupnow MF, et al. Topiramate in migraine prophylaxis: Long-term impact on resource utilization and cost. Headache 2007;47(4):500-510.
77. Bussone G, Diener HC, Pfeil J, et al. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomized trials. Int J Clin Tract 2005;59(8):961-968.
78. Winner P, Gendolla A, Stayer C, et al. Topiramate for migraine prevention in adolescents: A pooled analysis of efficacy and safety. Headache 2006;46(10):1503-1510.
79. Wenzel RG, Schwarz K, Padiyara RS. Topiramate for migraine prevention. Pharmacotherapy 2006;26(3):375-387.
80. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28(6):277-279.
81. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: A randomized blinded crossover study. Headache 2006;46(4):642-648.
82. Krymchantowski A, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Medscape Gen Med 2004;6(3):48.
83. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache 2006;46(5):804-807.
84. Ashkenazi A, Benlifer A, Korenblit J. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006;26(10):1199-1202.
85. Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007;47(3):402-412.
86. Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: A double-blind randomized placebo-controlled study. Clin Ther 2000;151(3):145-148.
87. Mathew N, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;141:119-128.
88. Steiner TJ, Findley LI, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:101-102.
89. Rapoport AM, Sheftell FD, Tepper SJ, et al. Levetiracetam in the preventive treatment of transformed migraine. Curr Ther Res 2005;66:212-221.
90. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. JAMA 1983;250:2500-2502.
91. Markley GH, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984;34:973-976.
92. Solomon GD. Verapamil in migraine prophylaxis: A five-year review. Headache 1989;29(7):425-427.
93. Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache 1988;28:260-262.
94. Kahan A, Weber S, Amor B, et al. Nifedipine in the treatment of migraine in patients with Raynaud's phenomenon. N Engl J Med 1983;308:1102-1103.
95. Lindegaard KF, Ovrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks: A double-blind, placebo-controlled crossover study. Headache 1980;20:96-98.
96. Sargent J, Solbach P, Damasio H, et al. A comparsion of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985;25:320-324.
97. Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985;35:1304-1310.
98. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985;42:582-584.
99. O'Neill BP, Mann JD. Aspirin prophylaxis in migraine. Lancet 1978;2:1179-1181.
100. Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin antiinflammatory drug, ketoprofen (19,583 r.p.) in migraine prophylaxis. Headache 1974;14:96-100.
101. Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolfenamic acid. Acta Neurol Scand 1982;66:105-111.
102. Diamond D, Solomon GD, Freitag FG, et al. Fenoprofen in the prophylaxis of migraine: A double-blind placebo controlled study. Headache 1987;27:246-249.
103. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: A placebo-controlled double-blind crossover. Headache 1992;32(10):509-513.
104. Saper JRT, Winner PK, Lake AE. An open-label dose titration study of the efficacy of tizanadine HCl tablets in chronic daily headache prophylaxis. Headache 2001;41:357-368.
105. Hering-Hanit R. Baclofen for prevention of migraine. Cephalalgia 1999;19(6):589-591.
106. Tronvik E, Stovner LJ, Heide G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA 2003;289;65-69.
107. Schrader H, Stovner L, Heide G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomized, placebo controlled, crossover study. BMJ 2001;322:19-22.
108. Paterna S, Di Pasquale P, D'Angelo A, et al. Angiotensin-Converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43:133-136.
109. Etminan M, Levine MA, Tomlinson G, et al. Efficacy of angiotensin II receptor antagonists in preventing headache: A systematic overview and meta-analysis. Am J Med 2002;112:642-646.
110. Sheftell F, Rapoport A, Weeks R, et al. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers. Headache 2000;40(2):158-163.
111. Brandes JL, Visser WH, Farmer MV, et al. Montelukast for migraine prophylaxis: A randomized double-blind, placebo-controlled study. Headache 2004;44:581-586.
112. LaPorta LD. Relief from migraine headache with aripiprazole treatment. Headache 2007;47(6):922-926.
113. Silberstein SD, Young WB, Hopkins MM, et al. Olanzapine in the treatment of refractory migraine and chronic daily headache (Abstract). Cephalalgia 2000;20:382.
114. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (Botox) for treatment of migraine. Semin Cutaneous Med Surg 2001;20(2):93-100.
115. Silberstein S, Mathew N, Saper J, et al. Botox Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-450.
116. Anand KS, Prasad A, Singh MM, et al. Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther 2006;13(3):183-187.
117. Vo AH, Satori R, Jabbari B, et al. Botulinum toxin type-A in the prevention of migraine: A double-blind controlled trial. Aviat Space Environ Med 2007;78(5 Suppl):B113-B118.
118. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type A prophylactic treatment of episodic migraine: A randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47(4):486-499.
119. Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7(10):688-696.
120. Freitag FG. Botulinum toxin type A in chronic migraine. Exp Rev Neurother 2007;7(5):463-470.
121. Medeiros FL, Medeiros PL, Valenca MM, et al. Simvastatin for migraine prevention. Headache 2007;47(6):855-856.
122. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: A double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-532.
123. Lipton RB, Gobel H, Einhaupl K, et al. Petasites hybridus root (butterbur) is an effective treatment for migraine. Neurology 2004;63:2240-2244.
124. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: Reanalysis of efficacy criteria. Eur Neurol 2004;51:89-97.
125. Sandor P, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713-715.
126. Peres MF, Zukerman E, da Cunha TF, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004;63;757.
127. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache 2004;44(9):885-890.
128. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 1998;50:466-470.
129. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257-263.
130. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine: A double-blind, placebo-controlled study. Cephalagia 1996;16:436-440.
131. MacGregor EA, Frith A, Ellis J, et al. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006;67:2154-2163.
132. Allais G, Bussone G, De Lorenzo C, et al. Advanced strategies of short-term prophylaxis in menstrual migraine: State of the art and prospects. Neurol Sci 2005(Suppl 2):S125-S129.
133. Martin V, Brandes JL. Strategies for optimizing management of menstrual migraine. J Fam Pract 2005;54(12):S1-S7.
134. Silberstein SD, Armellino JJ, Hoffman HD, et al. Treatment of menstruation-associated migraine with the non-prescription combination of acetaminophen, aspirin, and caffeine: Results from three randomized, placebo-controlled studies. Clin Ther 1999;21(3):475-491.
135. Sances G, Martignoni E, Fioroni L. Naproxen sodium in menstrual migraine prophylaxis: A double-blind placebo controlled study. Headache 1990;30(11):705-709.
136. Tepper SJ. Tailoring management strategies for the patient with menstrual migraine: Focus on prevention and treatment. Headache 2006;46(Suppl 2):S61-S68.
137. Newman LC, Lipton RB, Lay CI, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998;51:307-309.
138. Newman LC, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: A randomized, double-blind, placebo-controlled study. Neurology 2000;54:14-21.
139. Brandes JL, Smith T, Diamond M, Ames MH. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache 2007;47:886-894.
140. Silberstein SD, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63(2):261-269.
141. Silberstein SD. The role of sex hormones in headache. Neurology 1992;42(Suppl 2):37-42.
142. Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology 1991;41:786-793.
143. de Lignieres B, Vincens M, Mauvais-Jarvis P, et al. Prevention of menstrual migraine by percutaneous estradiol. Br Med J 1986;293:1540-1546.
144. Lichten EM, Bennett RS, Whitty AJ, et al. Efficacy of danazol in the control of hormonal migraine. J Reprod Med 1991;36(6):419-424.
145. O'Dea JP, Davis EH. Tamoxifen in the treatment of menstrual migraine. Neurology 1990;40:1470-1471.
146. Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology 1997;48:101-102.
147. Fox AW, Diamond ML, Spierings EL. Migraine during pregnancy: Options for therapy. CNS Drugs 2005;19(6):465-481.
148. Silberstein SD. Headaches in pregnancy. Neurol Clin 2004;(4):727-756.
149. Marcus DA. Headache in pregnancy. Curr Pain Headache Rep 2003;7:288-296.
150. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001;41:351-356.
151. Evans RW, Diamond ML. Expert opinion: Is sumatriptan use safe during pregnancy? Headache 2000;40:856-857.
152. Dey R, Khan S, Akhouri V, et al. Labetalol for prophylactic treatment of intractable migraine during pregnancy. Headache 2002;42:642-645.
153. Lewis D, Ashwal S, Hershey A, et al. Practice parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and Practice Committee of the Child Neurology Society. Neurology 2004;63:2215-2224.
154. Hershey A, Scott WP, LeCates S, et al. Effectiveness of nasal sumatriptan in 5- to 12-year-old children. Headache 2001;41:693-697.
155. Lewis DW, Winner P, Hershey AD, et al. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics 2007;120:390-396.
156. de Souza Carvalho D, Fragoso YD, Coelho FM, et al. Asthma plus migraine in childhood and adolescence: Prophylactic benefits with leukotriene receptor antagonist. Headache 2002;41:1044-1047.
157. Wang F, Van Den Eden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent headaches in children: A randomized, double-blind, placebo-controlled trial. Headache 2004;44(5):445-446.
158. Caruso JM, Brown WD, Exil G, et al. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache 2000;40:672-676.
159. Pakalnis A, Greenberg G, Drake ME, et al. Pediatric migraine prophylaxis with divalproex. J Child Neurol 2001;16:731-734.
160. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology 2006;67(2):246-251.
161. Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging 2006;23(6):461-489.
162. Martins KM, Bordini CA, Bigal ME, et al. Migraine in the elderly: A comparison with migraine in young adults. Headache 2006;46(2):312-316.
163. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998;56(5):811-824.
164. Evers S, Afra J, Frese A, et al. EFNS [European Federation of Neurological Societies] guideline on the drug treatment of migraine: Report of an EFNS Task Force. Eur J Neurol 2006;13:560-572.
165. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al., for the Canadian Headache Society. Guidelines for the diagnosis and management of migraine in clinical practice Can Med Assoc J 1997;156:1273-1287.
166. Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs. step care strategies for migraine: The Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000;284(20):2599-2605.